Possibility of Human Epidermal Growth Factor Receptor 2 Expression as a Treatment Selection Indicator in Early Triple-Negative Breast Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Human epidermal growth factor receptor 2 (HER2) expression in triple-negative breast cancer (TNBC) does not predict neoadjuvant chemotherapy response. However, HER2 status impacts distant disease-free survival and overall survival, suggesting aggressive treatment for HER2-negative patients.
Area Of Science
- Oncology
- Breast Cancer Research
- Molecular Diagnostics
Background
- Triple-negative breast cancer (TNBC) presents unique treatment challenges.
- Understanding human epidermal growth factor receptor 2 (HER2) expression is crucial for prognosticating outcomes in TNBC.
- The role of HER2 in predicting response to neoadjuvant chemotherapy (NAC) and survival in early-stage TNBC requires further elucidation.
Purpose Of The Study
- To investigate the association between HER2 expression levels and pathological complete response (pCR) rates following NAC in early-stage TNBC.
- To evaluate the correlation between HER2 expression and prognosis, including distant disease-free survival (DDFS) and overall survival (OS).
- To determine the impact of HER2 status on treatment strategies for TNBC.
Main Methods
- Retrospective analysis of 39 early-stage TNBC patients treated between 2012 and 2020.
- Assessment of HER2 expression levels using immunohistochemistry and fluorescence in situ hybridization (FISH).
- Correlation analysis of HER2 status with pCR rates, clinicopathological factors, DDFS, and OS.
Main Results
- No significant correlation was found between HER2 expression levels and pCR rates after NAC.
- HER2 expression levels showed a significant decrease after NAC (p = 0.001).
- A significant correlation was observed between HER2 status and DDFS (p = 0.032) and OS (p = 0.012), particularly for HER2-low and HER2 (0) statuses.
Conclusions
- HER2 expression level is not a predictor of pCR in TNBC patients undergoing NAC.
- HER2 status is significantly associated with prognosis (DDFS and OS) in early-stage TNBC.
- Patients with HER2 (0) status have a poorer prognosis and may benefit from more aggressive perioperative chemotherapy, potentially including immune checkpoint inhibitors.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...